DK4225297T3 - Kombinationsbehandling til behandling af cancer - Google Patents

Kombinationsbehandling til behandling af cancer Download PDF

Info

Publication number
DK4225297T3
DK4225297T3 DK21794474.3T DK21794474T DK4225297T3 DK 4225297 T3 DK4225297 T3 DK 4225297T3 DK 21794474 T DK21794474 T DK 21794474T DK 4225297 T3 DK4225297 T3 DK 4225297T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
combination therapy
therapy
combination
Prior art date
Application number
DK21794474.3T
Other languages
Danish (da)
English (en)
Inventor
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK4225297T3 publication Critical patent/DK4225297T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK21794474.3T 2020-10-08 2021-10-07 Kombinationsbehandling til behandling af cancer DK4225297T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
PCT/EP2021/077703 WO2022074124A1 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
DK4225297T3 true DK4225297T3 (da) 2025-01-02

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21794474.3T DK4225297T3 (da) 2020-10-08 2021-10-07 Kombinationsbehandling til behandling af cancer

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
HUE069249T2 (hu) 2025-02-28
ES3005507T3 (en) 2025-03-14
KR20230083291A (ko) 2023-06-09
PT4225297T (pt) 2024-12-30
EP4225297A1 (en) 2023-08-16
JP2023546362A (ja) 2023-11-02
FI4225297T3 (fi) 2024-12-10
US20230372333A1 (en) 2023-11-23
WO2022074124A1 (en) 2022-04-14
AU2021356123B2 (en) 2025-01-09
CA3197056A1 (en) 2022-04-14
EP4225297B1 (en) 2024-10-23
ZA202304965B (en) 2024-09-25
TW202228693A (zh) 2022-08-01
CN116194110B (zh) 2025-06-17
PL4225297T3 (pl) 2025-03-17
CN116194110A (zh) 2023-05-30
MX2023004156A (es) 2023-05-03
IL301687A (en) 2023-05-01
AU2021356123A1 (en) 2023-06-08
BR112023005160A2 (pt) 2023-04-18
JP7818585B2 (ja) 2026-02-20

Similar Documents

Publication Publication Date Title
DK4096717T3 (da) Behandling af cancer
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
EP4171548A4 (en) Combination therapy for treatment of cancer
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
EP3565558A4 (en) POLYTHERAPY FOR CANCER TREATMENT
ZA202206743B (en) Therapy for the treatment of cancer
IL281244A (en) Combination therapy for the treatment of liver disease
IL282093A (en) Combination therapy for cancer
DK3768830T5 (da) Cancerterapi
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
IL281845A (en) Combination therapy for the treatment of cancer
IL285155A (en) Metal chelator combination therapy for the treatment of cancer
DK4125842T3 (da) Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer
IT201900016760A1 (it) Dispositivo per il trattamento radioterapico di malati oncologici
EP4440623A4 (en) Polytherapy for the treatment of cancer
DK4340842T3 (da) Sotorasib til anvendelse ved behandling af kræft
DK4419526T3 (da) Heterocykliske forbindelser til anvendelse i behandlingen af cancer
DK4153232T3 (da) TNFalfa-immunkonjugatterapi til behandling af hjernetumorer
IL284162A (en) Integrated healing for cancer treatment
IL281281A (en) Combination therapy for the treatment of prostate cancer